Rockefeller Capital Management
HRTX icon

Rockefeller Capital Management’s Heron Therapeutics HRTX Stock Holding History

Rockefeller Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151 Sell
354
-932
-72% -$747 ﹤0.01% 4672
2026
Q1 		$1.03K Buy
1,286
+871
+210% +$1.01K ﹤0.01% 4483
2025
Q4 		$539 Buy
415
+354
+580% +$437 ﹤0.01% 4518
2025
Q3 		$77 Buy
+61
New +$97 ﹤0.01% 4378
2022
Q4 		– Sell
-200
Closed – – 4016
2022
Q3 		$0 Sell
200
-1,041
-84% -$4.07K ﹤0.01% 4094
2022
Q2 		$3K Buy
1,241
+1,041
+521% +$4.18K ﹤0.01% 3650
2022
Q1 		$1K Hold
200
– – ﹤0.01% 3738
2021
Q4 		$1K Sell
200
-900
-82% -$9.19K ﹤0.01% 3649
2021
Q3 		$11K Sell
1,100
-110
-9% -$1.34K ﹤0.01% 2849
2021
Q2 		$18K Hold
1,210
– – ﹤0.01% 2529
2021
Q1 		$19K Buy
1,210
+1,010
+505% +$18K ﹤0.01% 2303
2020
Q4 		$4K Hold
200
– – ﹤0.01% 2491
2020
Q3 		$2K Hold
200
– – ﹤0.01% 2413
2020
Q2 		$3K Hold
200
– – ﹤0.01% 2226
2020
Q1 		$2K Buy
+200
New +$3.76K ﹤0.01% 2178

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Rockefeller Capital Management's HRTX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Heron Therapeutics (HRTX) stake by 72% in Q2 2026, selling an estimated $747 and leaving 354 shares worth $151. The position accounts for ﹤0.01% of the portfolio, ranked #4672.

Rockefeller Capital Management first reported a position in HRTX in Q1 2020 and has held it in 15 quarters since. The position peaked at $19K in Q1 2021. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Rockefeller Capital Management held 354 shares of Heron Therapeutics worth $151 as of Q2 2026.
  • Rockefeller Capital Management sold 932 Heron Therapeutics shares in Q2 2026, an estimated $747.
  • Heron Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4672 holding.
  • Rockefeller Capital Management first reported a position in Heron Therapeutics in Q1 2020 and has held it in 15 quarters since.
  • Rockefeller Capital Management's Heron Therapeutics position peaked at $19K in Q1 2021.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.